Gov: Calif. could vaccinate more with supply boost

California is increasing the number of vaccines it distributes but could do much more if the supply was available, Gov. Gavin Newsom said Monday. (Feb. 22)

Video Transcript

GAVIN NEWSOM: It's also important and significant to highlight this stubborn fact, there's not enough vaccinations. There's not enough doses. There's not enough vaccines to accommodate the need and demand.

Just at this site, they're running about a third of capacity. Sites all across the state of California are toggling back, based upon limited supply. It's simply not what we're capable of administering, meaning we could do exponentially more, but nonetheless, we are seeing modest improvement week to week, and that's allowing us to not only take care of vaccinating the vaccinators and vaccinating our most vulnerable, our seniors, but as the mayor has been doing for now weeks and weeks, vaccinating our teachers as well so we can get our kids back into in-person instruction.

Recommended Stories

  • New vaccine delivery system starts in parts of California

    California's new system of delivering, tracking and scheduling coronavirus vaccines is being rolled out in select counties, a first step in Gov. Gavin Newsom's plan to smooth out what has been a confusing and disjointed rollout hampered by limited national supply. Newsom announced last month that his administration had tapped insurer Blue Shield to design and manage a centralized system to get doses out quickly and equitably. An initial list provided by the state showed 10 counties in the inland sections of central and Southern California chosen to be the first to make the transition to the Blue Shield system this week, although one county said Friday it would shift later.

  • Newsom recall effort closer to making ballot

    California Gov. Gavin Newsom recall effort moves closer to making the ballot as 1.1 million signatures are submitted; Recall Gavin Newsom senior adviser Randy Economy joins ‘Fox and Friends Weekend.’

  • Supreme Court won't hear 2020 election case that questioned some Pennsylvania ballots

    Three conservative justices on the high court said they would have heard the Pennsylvania election cases, one vote shy of the four needed.

  • Xavier Becerra: Biden’s Most Divisive Cabinet Nominee

    West Virginia Democratic senator Joe Manchin made news on Friday night when he announced his opposition to the confirmation of Neera Tanden, President Biden’s pick to run the Office of Management and Budget. Tanden’s “overtly partisan statements will have a toxic and detrimental impact on the important working relationship between members of Congress and the next director of the Office of Management and Budget,” Manchin said in a statement. “For this reason, I cannot support her nomination.” If Manchin really means what he said — if his opposition is rooted in principle and not an attempt at political triangulation — then he should also reject the nomination of Xavier Becerra to run the Department of Health and Human Services. Becerra’s transgressions are far graver than Tanden’s gratuitously insulting tweets, and his confirmation would have a much more toxic and detrimental impact on the country. As California attorney general, Becerra has been an exceptionally ruthless aggressor in the culture wars. He has attempted to use the power of the state to crush a wide array of average Americans — from religious dissenters to pro-life pregnancy counselors and independent journalists. In 2017, Becerra filed felony charges against the pro-life activists and citizen-journalists who had gone undercover to expose Planned Parenthood’s gruesome practice of selling the body parts of aborted babies to biotech companies. Becerra had not gone after animal-rights activists for similar investigative tactics. In response to Becerra’s actions, one writer at the left-wing magazine Mother Jones called the Planned Parenthood videos “a legitimate investigation, and no level of government should be in the business of chilling it.” Becerra was rebuked by the liberal editorial page of the Los Angeles Times for his “disturbing overreach.” In 2018, Becerra and the State of California were smacked down by the U.S. Supreme Court in the case NIFLA v. Becerra over a state law forcing pro-life pregnancy centers to advertise abortion. In 2019, Becerra aggressively opposed the merger of two religiously affiliated hospital chains in California because the resulting consolidated chain could reduce access to both abortion and gender-reassignment surgeries. In 2020, Becerra was rebuked for his zealous defense of a California law requiring abortion coverage in insurance plans offered by churches. The Office of Civil Rights at the Department of Health and Human Services ruled that California’s abortion mandate violated a federal law known as the Weldon amendment, which prohibits federal funding of states and localities that force health providers and insurers to participate in or cover abortion. Becerra refused to comply. In 2021 — in the middle of a once-in-a-century pandemic — it is hard to think of a worse choice than Becerra to run the Department of Health and Human Services. To fight the pandemic, the Biden administration needs a health and human services secretary who has the broad trust of the public, but it’s going to be impossible for Becerra to earn the trust of those who constitute nearly half the country and believe (with reason) that Becerra wants to crush them and drive them from the public square. Democrats only need to imagine the difficulty that a culture warrior such as Rick Santorum would have in convincing the residents of Berkeley, Calif., to “trust the science” about the benefits of a new vaccine. (The comparison is not entirely fair to Santorum: The former GOP Pennsylvania senator was a lightning-rod in the culture wars, but he had some experience with health policy and wasn’t nearly as zealous as Becerra.) What’s just as bad as Becerra’s lack of trust from the public is his lack of relevant experience. He has no experience in public health or medicine or at the Department of Health and Human Services. He lacks executive experience running a large and complex organization — the kind of experience that would be useful as the government distributes vaccines and adapts to new variants of the virus. Any Biden nominee to run HHS will share the president’s liberal views on abortion and transgender issues, but Becerra’s record guarantees that he will use HHS’s broad rulemaking authority to aggressively wage a culture war and alienate many Americans. There is nothing Becerra can say at his confirmation hearing on Tuesday that can erase that record. Many of Biden’s other nominees show that the president is more than capable of selecting qualified Cabinet members with bipartisan credibility. Treasury secretary Yellen, Secretary of State Blinken, and Secretary of Defense Austin were each confirmed by overwhelming bipartisan Senate majorities. It has been befuddling to many of Biden’s friends and foes alike that he chose an unqualified ideologue to run HHS during a pandemic. A majority of the Senate should reject Becerra and give Biden an opportunity to try again.

  • Pfizer Expands Production For COVID-19 Doses After Meeting With President: Bloomberg

    The U.S. President Joe Biden met with Pfizer Inc’s (NYSE: PFE) CEO Albert Bourla on Friday to discuss its COVID-19 vaccine stockpile estimated to be ready by Summer 2021, Bloomberg reports. The meeting took place at Pfizer’s manufacturing facility in Michigan. Bourla announced during the visit that he expects more than doubling the approximately 5 million vaccine doses per week it currently sends out in the coming weeks. The company said it would employ additional capacity at its Kalamazoo site to produce the vaccine’s formulation and a component of the vaccine, known as lipids. It will also increase lipid production capabilities at its plant in Groton, Connecticut, and add on fill-finish capacity at its site in McPherson, Kansas. Pfizer has also recruited two new contract manufacturers and is increasing the supply of raw materials from existing suppliers. Pfizer and its German partner BioNTech SE (NASDAQ: BNTX) will be able to deliver 120 million doses in the U.S. within the first quarter, Bourla told Bloomberg at the time. As of February 17, the companies had supplied the U.S. with 40 million doses. Globally, Pfizer and BioNTech aim to produce a total of 2 billion doses before year-end. Last week, Pfizer and BioNtech submitted COVID-19 vaccine stability data, suggesting that the shot can be stored in lower temperatures for two weeks. Price Action: PFE is down 0.3% at $34.35, while BNTX is up 0.7% at $116.5 in premarket trading on last check Monday. See more from BenzingaClick here for options trades from BenzingaPfizer Says South African Variant Could Significantly Reduce Vaccine Protection: ReutersShortage Of Giant Sterile Liners Threatens Global Vaccines Rollout: FT© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Japan vaccine supplies to be limited, delaying shots for elderly: minister

    Japan will only receive limited doses of COVID-19 vaccines for the first months of the rollout and shots for the elderly will be distributed gradually, the country's inoculation chief said. Pfizer Inc, the maker of Japan's only approved COVID-19 vaccine, is ramping up production in Europe, but those increased supplies are not likely to reach Japan until May, Administrative Reform Minister Taro Kono cautioned on Sunday in an interview with national broadcaster NHK. "We would like to start vaccinations for the elderly in April, but unfortunately the number of doses allocated to them will be very limited at first, so we want to start slowly," Kono said.

  • Vaccine trials fail to capture representative sample of Americans

    Note: Trials occurred in the U.S. between 2011 and 2020; Population reflects average U.S. Census figures for 2011 to 2018. Source: 2021 Flores LE et al. JAMA Network Open; Chart: Michelle McGhee/AxiosU.S. vaccine trials over the past decade have not included enough seniors and Hispanic and Black adults, and show a failure to report needed demographic details, according to a study published in JAMA Network Open Friday looking at a large sample of trials.Why it matters: By not capturing a representative sample of Americans, vaccine trials cannot fully demonstrate the safety and effectiveness for all people and miss out on an opportunity to build trust within underrepresented communities — something vitally important in the COVID-19 pandemic, two experts tell Axios.Stay on top of the latest market trends and economic insights with Axios Markets. Subscribe for free"It makes it harder to ensure that our drugs and medicines are going to work for all people," says Namandjé Bumpus, director of the department of pharmacology and molecular sciences at Johns Hopkins University School of Medicine."There are certain genetic variants, particularly involved in drug processing, that seem to very closely track with geography and ancestral origin and can be more prevalent in certain groups than others," says Bumpus, who was not part of the study.Study co-author Steven Pergam says the "downstream effect" of inclusivity is important for building trust in communities for vaccines, particularly "when you look at the data about the clinical trial and you see people like yourself included, and you show the safety and efficacy in those groups."The state of play: Despite efforts by the NIH and FDA to require more trials to report age, sex, race and ethnicity, most do not comply completely. Examining data from 230 vaccine trials between mid-2011 to mid-2020 with 219,555 participants, the JAMA study found all reported age and sex, but only 58% reported race and 34% ethnicity."That's a big issue. The reporting is not happening, despite the policies," Bumpus says.While the study paints an incomplete picture partly because of that underreporting, "what we're seeing here is a microcosm for what's going on more broadly with both vaccines and drugs," she says. These are reproducible overall trends in trials, she adds."We need more outreach and education" to combat the misinformation and long-term distrust that people of color have in the medical community overall and in vaccines specifically, Bumpus says. Besides the discrepancy in underreporting by most trials, Pergam, associate professor in the Vaccine and Infectious Disease Division at Fred Hutchinson Cancer Research Center, says an examination of adult trials found:Hispanic (12%) and Black (11%) adults, as well as seniors (12%), were not represented equitably, while white people (78%) and women (56%) tended to be overrepresented.The "definitive" phase three for clinical trials — testing large numbers of the population with the goal of gaining FDA approval — actually had a less-diverse population than the initial trial phases.Between the lines: Finding less inclusiveness in phase three trials is concerning, and may be due to their focus on "ease and speed" that tends to preclude underrepresented communities who are not as established in the medical system, Pergam says."The problem is when you aim for speed, you often miss these groups because it does take time and effort ... and you need to prioritize this."COVID-19 trials can serve as a model, Pergam says. "As an example, the Moderna trial did slow down enrollment to make sure they had adequate enrollment of underrepresented minorities, which I think was really key. They put time, they put money, they put people in these groups. They met with community groups ahead of time."One positive takeaway is that it "debunks this myth that's so prominent right now, that [Black and Hispanic Americans] don't enroll in clinical trials. Clearly we do," Bumpus says. "This [study] shows we're underrepresented but it also shows there clearly is a willingness. We are there. So there are things that can be done to improve that."The bottom line: Federal agencies and science publications need to get serious about putting some teeth into their policies for studies to report demographics, they said. And trial organizers need to make a concerted effort to reach out to underrepresented communities and set specific diversity enrollment targets.Check out: Axios' Get Smart videos on vaccines.Go deeper: The cost of racial disparities in clinical trialsMore from Axios: Sign up to get the latest market trends with Axios Markets. Subscribe for free

  • MDMA could be used to treat alcohol addiction

    The drug MDMA could be used to treat alcohol addiction, a new study by British researchers has said. The study, published in the Journal of Psychopharmacology, is the world’s first and showed that people who were given the drug, also known as Ecstasy, were dramatically more successful in limiting their drinking, compared with patients who received more traditional treatments. The Class A drug is thought to suppress a region of the brain known as the amygdala, which allows patients to confront painful memories from their past without becoming overwhelmed. Researchers in Bristol studied a group of 14 patients who took part in ten psychotherapy sessions over eight weeks. During two of the sessions, on weeks three and seven, they were given a dose of 125mg of MDMA, followed by another 62.4mg two hours later. Each session lasted between six and eight hours and took place in a hospital with a psychiatrist and a psychologist present. After the MDMA sessions, patients stay overnight and are checked every day for the following week to assess their sleep quality, mood and potential suicide risk. Over the following nine months, researchers collected data on drinking behaviour. Of the 14 participants who had the course of MDMA-assisted psychotherapy, 11 were drinking fewer than 14 units of alcohol per week nine months later, including nine who were totally abstinent. Lead author, Ben Sessa of Imperial College, told the Times: “It turns off the fear centre in the brain. “That allows the patient to reflect upon painful, traumatic memories that they would normally avoid. It allows you, basically, to carry out the psychotherapy that you wouldn’t normally be able to do. “The potential is huge — pretty much all of my patients with alcoholism have a history of trauma.” In the United States, researchers have carried out similar trials to look at whether MDMA can be used to treat post-traumatic stress disorder. This study found no evidence of drug withdrawal or unpleasant comedown symptoms from the drug. The money for the study was donated to Imperial College by the Alexander Mosley Charitable Trust. Ends

  • UN to rich nations: Don't undermine COVAX vaccine program

    The head of the World Health Organization pleaded with rich countries on Monday to check before ordering additional COVID-19 vaccine shots for themselves whether that undermines efforts to get vaccine shots to poorer nations. Wealthy nations have snapped up several billion vaccine doses while some countries in the developing world have little or none. European nations have given financial support to the U.N.-backed COVAX effort to get vaccines to the world’s most vulnerable people and are considering sharing some of their own doses — though they haven't specified when or exactly how many.

  • We Gave 4 Men a Style Transformation After They Hit Their Fitness Goals

    Some slimmed down. Some bulked up. Some got healthy. And they all needed some new clothes to match their stronger, healthier bodies.

  • US borders with Canada and Mexico to remain shut until March 21, marking full year of closures

    DHS announced the U.S., Canada and Mexico have agreed to keep land borders closed through at least March 21, making it a full year.

  • Elon Musk set up a COVID-19 antibody study at SpaceX and got 4,300 employees to take part

    Elon Musk reportedly took a personal interest in the study, and asked researchers to brief himself and top SpaceX executives.

  • Is It OK to Delay Your Second Dose of the COVID-19 Vaccine? Here’s What Doctors Say

    Thankfully, you have a bit of wiggle room if your appointment gets canceled.

  • Some unemployed Californians say they are fraud victims but bank won't unfreeze their accounts

    California's state unemployment agency is still struggling to deal with a crush of claims during the pandemic - and a staggering amount of fraud. But many unemployed Californians with legitimate claims of fraud tell CBS News they question whether the bank that supplies the debit cards which hold the unemployment funds is really investigating. Anna Werner reports.

  • Work inside or outside the GOP? ‘Never Trump’ Republicans split over next steps

    With their defeated nemesis still looming over the GOP, anti-Trump Republicans are debating where they fit in the two-party system.

  • In Los Angeles, Pandemic Life Depends on Where You Live

    As the sprawling city hit its Covid-19 peak in January, some families were devastated — and some others didn't even slow down

  • Please Stop With The Medical Gaslighting

    I’m so sick—pun intended--of the medical gaslighting, because it only makes my constant suffering worse.

  • Supporting this Black-owned coffee brand helps change the lives of at-risk youth

    The business donates five percent of every purchase to nonprofit organizations. The post Supporting this Black-owned coffee brand helps change the lives of at-risk youth appeared first on In The Know.

  • Jim Carrey retires from political cartoons now that Donald Trump ('Orange Julius Caesar') is no longer president

    To reclaim "a little neurological bandwidth," Jim Carrey said on Twitter that he will no longer create anti-Donald Trump political protest cartoons.

  • As US death toll nears 500K, Dr. Anthony Fauci says Americans could be wearing masks in 2022: Latest COVID-19 updates

    Dr. Anthony Fauci says it's "possible" we will be wearing masks into 2022. A Johns Hopkins expert disagrees. Latest COVID-19 news.